Investors’ Presentation, April 2018
Disclaimer: Forward-looking statements � This document contains certain statements that are not historical facts � The Company is an emerging clinical-stage healthcare company and may be forward-looking statements that are subject to a variety of with higher investment risk and higher potential compared to larger risks and uncertainties. There are a number of important factors that or more established companies. If one or more of these risks or could cause actual results to differ materially from those projected or uncertainties materialises, or if underlying assumptions prove suggested in any forward-looking statement made by SynDermix (“the incorrect, the Company's actual results may vary materially from Company”). These factors include (but are not limited to): ------------------ those expected, estimated or projected. Given these risks and uncertainties, potential investors should not place any reliance i. The Company's and/or the Company's partners’ ability to on forward-looking statements successfully complete product research and development � Without limiting the generality of the foregoing, no assurance is ii. The Company's and/or the Company's partners’ ability to obtain given as to when the Company’s products will be launched or required governmental approvals (including product and patent licensed or whether that launch or licensing will be commercially approvals; the impact of industry and government regulation; the successful, and words such as "may", "will", "to", "expect", "plan", difficulty of predicting regulatory authority approvals; the regulatory "believe", "anticipate", "intend", "could", "would", "estimate" or environment and changes in the health policies and structures of "continue" or the negative or other variations thereof or comparable various countries) terminology is intended to identify forward-looking statements iii. The acceptance and demand for new products and technologies, � Neither the Company nor its directors undertake any obligation to and the Company's ability to attract and/or maintain update forward-looking statements or risk factors other than as manufacturing, sales, distribution and marketing partners required by applicable law, whether as a result of new information, future events or otherwise iv. The Company's and/or the Company's partners’ ability to develop and commercialise products before its competitors and the impact of competitive products and pricing; the availability and pricing of ingredients used in the manufacturing of products and uncertainties regarding market acceptance of innovative products, be they newly launched, currently being sold or in development. In addition, significant fluctuations in financial results may occur as a result of the timing of milestone payments and the timing of costs and expenses related to the Company's research and development programme 2
CONTENTS THE COMPANY p. 4 THE PRODUCT PORTFOLIO p. 10 THE WAY FORWARD p. 14 3
1 THE COMPANY 4
About SynDermix SynDermix is a Swiss clinical-stage biotech company funded by private investors Our vision is to become a global leading-edge developer of unparalleled products that will be continuously relevant to improving peoples’ health and well-being We value innovation, creativity, integrity, dedication and fairness ; we believe that success is achieved by people with a diverse range of talents and through partnerships; we maintain a commitment to sustainability in our development ethics and collaborations; we are driven by passion and professionalism 5
Business model and operations SynDermix identifies and acquires the rights to innovative products , which it develops until a robust demonstration of their clinical value and a strengthening of their innovation value (IP); the Company then enters into corporate partnerships for market access Our focus is on products of natural origin that satisfy unmet healthcare needs and wellcare demands; this strategy enables us to benefit from accelerated timelines to market access — through Orphan Drug Designation, registration as a medical device or as a cosmetic product We operate a lean structure , which leverages the complementary expertise of a seasoned executive team and a broad network of selected service providers and key opinion leaders; the creation of a formal Scientific Advisory Board is in progress 6
SynDermix in the biopharma industry SynDermix Early-stage biotech Big Pharma Emphasis on demonstration Emphasis on Emphasis on of clinical value & research, drug drug refinement, strengthening discovery and sales & marketing of IP Value chain Leading-edge securing IP products High risk Chemically- Risk mitigation Products of natural origin synthesised Single product drugs & biologics Multiple platforms (usually) New IP protection & pipelines Lean structure Asset heavy & adaptability Initial investments Investments enterprise model difficult to secure Accelerated timelines 7
Management team Dieter Hemmer — Chief Executive Officer Anthony Lockett , MD, PhD, MBA 15 years’ senior executive experience at Nestlé as Head of the — Research & Manufacturing Strategic Business Unit (Nestlé Professional Food Services) and Over 25 years’ experience in the pharmaceutical and medical devices Chairman of the Pro Gastronomia Nestlé Foundation. Prior to industry. For the last 13 years he has been part of a team of consultants Nestlé, he spent 22 years in a number of senior executive positions advising clients on the regulatory and clinical strategy for product with Lufthansa, including Head of Global Inflight Service and development and has acted as a CMO for an AIM listed company. He is Managing Director for Lufthansa Service (LSG) Asia. BSc in also a Professor at King’s College, London Economics from FHS Heidelberg and management education at INSEAD, London Business School and IMD Carlos Camozzi , MD, PhD, MBA Angel Benito , LL.M — Executive Vice President — Clinical & Regulatory An entrepreneur with over 20 years’ experience in banking and asset management. Served as a manager for Credit Suisse, Bank Over 25 years’ international senior management experience in the Sarasin and Hyposwiss. In 2010 he formed his independent asset biopharmaceutical industry (Roche, American Cyanamid, Mepha AG, management company and subsequently several other Orphan Europe, UniQure, Orphazyme). Successfully led several companies regulatory achievements with both the EMA and the FDA. He is a permanent expert in the European Commission for Eureka and H2020 grant frames, and an expert in rare diseases and orphan drugs Rolf Küng , MBA — Finance & Controlling Konstantinos Efthymiopo ulos , PharmD, PhD, MBA A Swiss Certified Accountant and co-founder of the Institute For — Medical Marketing & Business Development Innovative Trading (IFIT) in 1998. 17 years’ experience in auditing Over 25 years’ international experience in big pharma, biotech and (Touché Ross, Deloitte Haskins & Sells, Grant Thornton and others). VC-backed companies (Farmitalia-Carlo Erba, Glaxo/GlaxoWelcome, Has been a director and CEO of several companies within the IFIT Serono, Eurand, Funxional Therapeutics, Index Ventures) at Group with a focus on business projects in Europe and overseas, increasingly senior levels that culminated in CSO, CEO and board and is currently a consultant to ARIA Capital Management with positions. He is currently the Chairman of the Board of Synaffix BV and offices in the UK, UAE, Greece and Switzerland Biopôle SA 8
Board of Directors Dimitri Dimitriou , MSc — Vice Chairman Alexander Ospelt , LL.M, PhD 25 years’ experience in the pharmaceutical and biotech industry. He — Chairman of the Board is the CEO of ImmuPharma plc, a pharmaceutical company listed on Founder of the law firm Ospelt & Partners Attorneys at Law Ltd. AIM of the London Stock Exchange. Past roles include senior in 1997. Has been active in politics and numerous associations; is positions in business development with GlaxoSmithKline and Bristol- currently the President of the Foundation for crisis intervention, Myers Squibb and earlier appointments with Procter & Gamble and Liechtenstein (KIT) and member of the Scientific Advisory Board Novartis (Sandoz). Mr Dimitriou is also President of Dragon Finance of the Private University Liechtenstein, and was a member of the AG, a Swiss company providing business development and Board of the European Advocates’ Association (DACH) and management services Chairman of the Board of Liechtenstein Life Assurance Ltd. Dr. Ospelt has published several academic studies Laura Piccinini — Director Dieter Hemmer — Delegate of the Board 25 years’ experience in the medical device industry, including (See Management Team on previous page) roles as President with full P&L responsibility across the international markets for several American multinational companies such as Mallinckrodt, Tyco, Covidien and Acelity. Currently she works for Nobel Biocare, a Danaher Company, in an executive role. Ms Piccinini is a member of the Global Summit of Women, Medical Device Industry. She has been awarded many honours, including, the Mallinckrodt Chairman's Award for best performance worldwide in 2005, and the Tyco CEO Award for best performance worldwide in 2007 and 2008 9
2 THE PRODUCT PORTFOLIO 10
Recommend
More recommend
